Dezocine

Dezocine

SCHEMBL9685743

C[C@@]12CCCCCC(Cc3ccc(O)cc31)C2N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRK1OPRM1

The experimentally established mechanism targets of Dezocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 13/20 1.00
OPRK1 known ✓ P41145 6/20 0.63
OPRD1 P41143 6/20 0.63
HSD11B1 P28845 1/20 0.46
SIGMAR1 Q99720 3/20 0.46
MRGPRX2 Q96LB1 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dezocine SCHEMBL29811203 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL29682715 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL12720257 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL11874182 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL3072 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL7781933 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL11874190 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL1369581 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL21081189 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1
Dezocine SCHEMBL25583319 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1HSD11B1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4957909-A Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents AMERICAN HOME PRODUCTS CORPORATION (US) 1990-09-18 US claimed
US-4605671-A Parenteral formulation AMERICAN HOME PRODUCTS CORPORATION (US) 1986-08-12 US claimed
EP-0180303-A1 Parenteral composition AMERICAN HOME PRODUCTS CORPORATION (US) 1986-05-07 EP claimed
US-4150147-A 13B-AMINO-5,6,7,8,9,10,11,12-OCTAHYDRO-5A-METHYL-5,11, -METHANOBENZOCYCLODECEN-3-OL AMERICAN HOME PRODUCTS CORPORATION (US) 1979-04-17 US claimed
US-4001331-A ANTIINFLAMMATORY, ANALGESIC AMERICAN HOME PRODUCTS CORPORATION (US) 1977-01-04 US claimed
US-3979434-A ANALGESICS, ANTIINFLAMMATORY AMERICAN HOME PRODUCTS CORPORATION (US) 1976-09-07 US claimed
US-20170216279-A1 METHODS FOR TREATING DEPRESSIVE SYMPTOMS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2017-08-03 US disclosed
US-5132401-A MB-35 a peptide enhancing the production of growth hormone and prolactin from the anterior pituitary GEORGE WASHINGTON UNIVERSITY, OFFICE OF SPONSORED RESEARCH (US) 1992-07-21 US disclosed
US-4957909-A Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents AMERICAN HOME PRODUCTS CORPORATION (US) 1990-09-18 US disclosed
US-4924008-A Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents AMERICAN HOME PRODUCTS CORPORATION (US) 1990-05-08 US disclosed
US-4605671-A Parenteral formulation AMERICAN HOME PRODUCTS CORPORATION (US) 1986-08-12 US disclosed
US-4150147-A 13B-AMINO-5,6,7,8,9,10,11,12-OCTAHYDRO-5A-METHYL-5,11, -METHANOBENZOCYCLODECEN-3-OL AMERICAN HOME PRODUCTS CORPORATION (US) 1979-04-17 US disclosed
US-4150147-A 13B-AMINO-5,6,7,8,9,10,11,12-OCTAHYDRO-5A-METHYL-5,11, -METHANOBENZOCYCLODECEN-3-OL AMERICAN HOME PRODUCTS CORPORATION (US) 1979-04-17 US disclosed
US-4001326-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1977-01-04 US disclosed
US-3979434-A ANALGESICS, ANTIINFLAMMATORY AMERICAN HOME PRODUCTS CORPORATION (US) 1976-09-07 US disclosed
US-3976696-A ANALGESIC, ANTIINFLAMMATORY AMERICAN HOME PRODUCTS CORPORATION (US) 1976-08-24 US disclosed
US-3976693-A ANALGESIC, ANTIINFLAMMATORY AMERICAN HOME PRODUCTS CORPORATION (US) 1976-08-24 US disclosed
US-3957872-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1976-05-18 US disclosed
US-3937736-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1976-02-10 US disclosed
US-3931328-A CARBURETOR AMERICAN HOME PRODUCTS CORPORATION (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216279-A1 METHODS FOR TREATING DEPRESSIVE SYMPTOMS OPRM1, OPRL1, OPRK1 OPRM1 1/4885OPRK1 3/4885OPRD1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.